Our international and interprofessional perspective paper on the ICUAW research agenda has been published in #ICM. Fantastic collaboration! Fulltext: https://t.co/DX2dklbvuw

🔥 HOT DEBATE at #lives2025 organized by The FREM section on ICU nutrition ➡️EN vs. PN:"EN first" & sPN to prevent underfeeding? ➡️Timing: How do we practically evaluate anabolic & metabolic readines ➡️Risks of Delay: What are the costs of underfeeding vs. dangers of forcing nur

En route to beautiful Prague for the European Society of Clinical Nutrition and Metabolism Congress. Excited to share the results of our TARGET Protein Trial on Tuesday 8:30am and seeing lots of familiar faces. If we haven’t met, come say hi! 👋🏻

Career highlight! Honoured to present @ProteinTarget with @msummo2 at @CritCareReviews in Belfast. You can read all about the trial in JAMA: https://t.co/EMIwL99b86 Or watch the full recording at: https://t.co/3irh9Rr5ol

Great way to end a busy fortnight of conferences!

A glorious Summer's day on the Giants Causeway..... #CCR25 Faculty Day Out

Augmenting enteral protein did not improve outcomes for critically ill patients compared with standard protein levels in the intensive care setting. #CCR25 @CritCareReviews https://t.co/GDpQJ68zpE

3. Lower protein doses (1.2g protein/kg/day) increased to goal over the first 4 days of ICU should be considered. 4. Future work may target the time to ⬆️ protein doses, given the impact of lower protein dose on muscle mass/malnutrition, potentially guided by urea levels.

My interpretation: 1. Short-term early higher dose protein feeding does not impact outcomes in critically ill patients. 2. Caution should be taken particularly for patients with an AKI at baseline.

For sub-groups, there was heterogeneity of treatment effect in those receiving mechanical ventilation (P = 0.02; very low credibility) and those receiving new kidney replacement therapy at baseline (P < .001; moderate credibility).

Blood urea increased from day 1 to 10 from 7.3 to 13.0 in the augmented group to 7.5 to 10.6 in the usual care group.

For the primary outcome, there was no difference in number of days free of the index hospital and alive at day 90: augmented protein: 62 (0-77) vs usual protein: 64 (0- 77) days; median diff -1.97 (95% CI -7.24, 3.30). There were no differences in any secondary outcome.

3397 patients (64% M, ~61y, ~80% IMV, APACHE 19, BMI 27) were recruited with high trial compliance. Mean protein doses (noted this data is for a subset of patients only) were lower than previous trials and with a mean duration of feeding of ~3.5 days.

We conducted a cluster randomised, double-crossover, clinical trial comparing augmented (Nutrison Protein Intense 100g protein/L) versus usual protein (Nutrison Protein Plus 63g/L) delivery in all patients receiving enteral nutrition in ICU. 8 ICUs participated for 12 months.

Meta-analysis mentioned in the @ProteinTarget editorial- shows harm in sub-group. Also shows signal for improved physical outcomes https://t.co/kkLMFeCQQu #ccr25

Seminal work by @LSChapple and team mentioned in the @ProteinTarget editorial #ccr25 Muscle Protein Synthesis after Protein Administration in Critical Illness | American Journal of Respiratory and Critical Care Medicine

Such a pleasure to present the @ProteinTarget trial at this incredible venue.

🚨 ENCOMPASS TRIAL Results at #CCR25🚨 📍 8 hospitals 👥 4032 patients 📊 Stepped-wedge cluster RCT 🎯 Tests STAR: nurse-led, telehealth care for high-risk sepsis survivors 🩺 Outcomes: 90-day readmission or death 📺 Free livestream — but it’s better in person!

Looking forward to presenting the results of @ProteinTarget in June. What a great line up for the editorial/panel!

Congratulations to all Vars candidates and the final award winners. Women powerhouse! 👏🏻